Loading
A phase 2 trial of cemiplimab and fianlimab in colorectal cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer is a phase 2, interventional study registered as NCT06205836 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 44 participants, started 2024-06-13 and due to reach its primary completion in 2030-05. Interventions recorded: Cemiplimab; Fianlimab. Conditions listed: Colorectal Cancer. Primary outcome: Complete Response Rate. Colorectal eligibility wording from the registry: "* Have histologically proven localized or locally advanced mismatch repair deficient (dMMR) or microsatellite unstable (MSI-H) colorectal cancer". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Fianlimab, Regeneron, Cemiplimab, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Regeneron, Cemiplimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cemiplimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Fianlimab, Regeneron, Cemiplimab, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.